Company profile: Pheon Therapeutics
1.1 - Company Overview
Company description
- Provider of antibody-drug conjugate (ADC) programs for difficult-to-treat cancers. Offerings include PHN-010, an ADC targeting a transmembrane protein over-expressed in multiple solid tumors with low expression in healthy tissues; development of first-in-class solid tumor programs with in vivo proof of concept; and proprietary payloads to overcome resistance, featuring novel modes of action and tunable potency.
Products and services
- Novel oncology targets: Architects first-in-class solid tumor programs demonstrating in vivo Proof of Concept, with additional candidates under evaluation across hard-to-treat indications
- PHN-010: Engineers an IND-enabling ADC targeting a transmembrane protein over-expressed in multiple solid tumors with low healthy-tissue expression, advancing toward Investigational New Drug submission by 2023/2024
- Proprietary payloads: Develops custom-engineered payloads to overcome resistance to traditional cytotoxic payloads, featuring novel Modes of Action and tuneable potency for ADC applications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pheon Therapeutics
Bicycle Therapeutics
HQ: United Kingdom
Website
- Description: Provider of clinical-stage biotherapeutics based on Bicycles—synthetic short peptides constrained into two loops—focused on oncology. Offerings include Bicycle Toxin Conjugates® delivering toxins to tumors, Bicycle Radio Conjugates delivering radioisotopes, and Bicycle TICA™ linking tumor-targeting Bicycles with immune agonists. Pipeline includes BT7480 (Nectin-4/CD137) and BT7455 (EphA2/CD137). Collaborative research beyond oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bicycle Therapeutics company profile →
Dako
HQ: Denmark
Website
- Description: Provider of reagents, instruments, and software for cancer diagnostics to hospital and research laboratories, offering pathology solutions including diagnostic antibodies, IHC/ISH and flow cytometry reagents; staining and image analysis instruments; molecular and companion diagnostics; and pharmacodiagnostic kits (pharmDx).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dako company profile →
AvenCell Therapeutics
HQ: United States
Website
- Description: Provider of switchable and allogeneic CAR-T cell therapy platforms, including a Universal Switchable CAR with soluble targeting modules for hematologic malignancies and solid tumors; a CRISPR/Cas9-based platform enabling off-the-shelf CAR-T that overcomes graft-versus-host disease and immune rejection; and therapies AVC-101 (CD123 autologous) and AVC-201 (allogeneic UniCAR) for relapsed/refractory AML.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AvenCell Therapeutics company profile →
Synimmune
HQ: Germany
Website
- Description: Provider of innovative mono- and bispecific anti-tumor antibodies for treating life-threatening diseases, focusing on orphan hematopoietic malignancies; lead product candidate is the antibody FLYSYN.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synimmune company profile →
Aurealis Therapeutics
HQ: Finland
Website
- Description: Provider of cell and gene therapies for chronic wounds and complex inflammatory diseases. Its four-in-one biologic AUP-16 is a genetically engineered Lactococcus cremoris producing therapeutic proteins to halt inflammation, induce blood vessel growth, and promote tissue formation for diabetic foot, venous leg, and pressure ulcers. AUP-55 is in pre-clinical development for ovarian and bladder cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aurealis Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pheon Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pheon Therapeutics
2.2 - Growth funds investing in similar companies to Pheon Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pheon Therapeutics
4.2 - Public trading comparable groups for Pheon Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →